-
Categories
-
Pharmaceutical Intermediates
-
Active Pharmaceutical Ingredients
-
Food Additives
- Industrial Coatings
- Agrochemicals
- Dyes and Pigments
- Surfactant
- Flavors and Fragrances
- Chemical Reagents
- Catalyst and Auxiliary
- Natural Products
- Inorganic Chemistry
-
Organic Chemistry
-
Biochemical Engineering
- Analytical Chemistry
- Cosmetic Ingredient
-
Pharmaceutical Intermediates
Promotion
ECHEMI Mall
Wholesale
Weekly Price
Exhibition
News
-
Trade Service
Sorafenib has always been the first-line standard treatment for patients with advanced hepatocellular carcinoma.
Although immunotherapy is now challenging this status, it still maintains a good therapeutic effect in hepatitis C (HCV) seropositive patients
.
This study aims to explore the tumor progression rate of HCV-related hepatocellular carcinoma patients treated with sorafenib, and to analyze the correlation with the overall survival rate and viral status
Sorafenib has always been the first-line standard treatment for patients with advanced hepatocellular carcinoma.
The researchers used a series of data from international clinical trials and applied a joint model to combine the survival rate of HCV patients with the disease progression over time to estimate the tumor growth rate assessed by tumor burden and serum alpha-fetoprotein, as well as sorafenib The effect of treatment on liver function
.
The results of this study show that high tumor burden at baseline is associated with an increased risk of death
.
Compared with patients who died during the study, tumor burden-related progression was very low in patients who were still alive at the end of the study
This study confirmed that sorafenib treatment can improve the survival rate of patients with advanced hepatocellular carcinoma.
The mechanism is mainly caused by reducing the tumor growth rate of HCV- infected patients and preventing liver function deterioration
.
The mechanism is mainly caused by reducing the tumor growth rate of HCV- infected patients and preventing liver function deterioration
.
Infection prevention
Original source:
Ruwanthi Kolamunnage-Dona.
Sorafenib is associated with a reduced rate of tumour growth and liver function deterioration in HCV-induced hepatocellular carcinoma in this message
